Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

Adaptimmune Therapeutics PLC (ADAP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
07/10/2023 SC 13G/A Matrix Capital Management Company, LP reports a 17.3% stake in Adaptimmune Therapeutics PLC
06/29/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/29/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/29/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "RULES of the ADAPTIMMUNE THERAPEUTICS PLC 2015 SHARE OPTION SCHEME Adopted by the Company on 16 March 2015 Amended on 15 April 2015, 13 January 2016, 18 December 2017 and 29 June 2023 CONTENTS 1. DEFINITIONS 3 2. ELIGIBILITY FOR EMI OPTIONS 9 3. GRANT OF OPTIONS 9 3a. SCHEME LIMIT 11 4. OPTION PRICE 13 5. VESTING SCHEDULE AND PERFORMANCE TARGETS 13 6. LIMITS 15 7. EXERCISE and Lapse OF OPTIONS 15 8. MANNER OF EXERCISE OF OPTIONS 18 9. TAX LIABILITIES 20 10. NON-TRANSFERABILITY OF OPTIONS 21 11. TAKEOVERS 21 12. QUALIFYING EXCHANGE OF SHARES 22 13. sale 22 14. listing 22 15. VARIATION OF SHARE CAPITAL 23 16. RELATIONSHIP WITH EMPLOYMENT CONTRACT 24 17. VARIATIONS AND TERMINATION 24 18. HMRC REQUESTS 25 19. EMI 25 20. GENERAL 25 21. GOVERNING LAW AND JURISDICTION 26 Page 2 RULES OF THE ADAPT...",
"RULES of the ADAPTIMMUNE THERAPEUTICS PLC 2016 EMPLOYEE SHARE OPTION SCHEME Adopted by the Company on 14 January 2016 and amended on 18 December 2017 and 29 June 2023 CONTENTS 1. DEFINITIONS 3 2. ELIGIBILITY FOR EMI OPTIONS 9 3. GRANT OF OPTIONS 9 3a. SCHEME LIMIT 12 4. OPTION PRICE 13 5. VESTING SCHEDULE AND PERFORMANCE TARGETS 13 6. LIMITS 14 7. EXERCISE and Lapse OF OPTIONS 15 8. MANNER OF EXERCISE OF OPTIONS 17 9. TAX LIABILITIES 19 10. NON-TRANSFERABILITY OF OPTIONS 21 11. TAKEOVERS 21 12. QUALIFYING EXCHANGE OF SHARES 21 13. sale 22 14. listing 22 15. VARIATION OF SHARE CAPITAL 22 16. RELATIONSHIP WITH EMPLOYMENT CONTRACT 23 17. VARIATIONS AND TERMINATION 23 18. HMRC REQUESTS 24 19. EMI 24 20. GENERAL 24 21. GOVERNING LAW AND JURISDICTION 25 Page 2 RULES OF THE ADAPTIMMUNE THERAPEUTI..."
06/01/2023 8-K Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; Election of Directors; Appoin...
Docs: "CONFIDENTIAL",
"Letter of appointment The board of directors of Adaptimmune Therapeutics plc is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Remuneration Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be based in, and perform your role as a non-executive, independent director and as a member of the Board's Remuneration Committee from [*]. This letter sets out the main terms of your appointment. If you need any more information, please let me know. By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restrictions which prevent you from holding office as a d...",
"Letter of appointment The board of directors of Adaptimmune Therapeutics plc is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Corporate Governance and Nominating Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be based in, and perform your role as a non-executive, independent director and as a member of the Board's Corporate Governance and Nominating Committee from [*]. This letter sets out the main terms of your appointment. If you need any more information, please let me know. By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restriction...",
"Letter of appointment The board of directors of Adaptimmune Therapeutics plc is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Audit Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be based in, and perform your role as a non-executive, independent director and as a member of the Board's Audit Committee from [*]. This letter sets out the main terms of your appointment. If you need any more information, please let me know. By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restrictions which prevent you from holding office as a director. 1. AP...",
"Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023 Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelin Preclinical programs targeting PRAME and CD70 in IND-enabling studies Adaptimmune funded into early 2026 with multiple value creating catalysts Webcast to be held tomorrow, June 2nd at 8 a.m. EDT: https://www.gowebcasting.com/12589"
05/30/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/12/2023 8-K Quarterly results
04/21/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/20/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
04/18/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
04/05/2023 S-4 Form S-4 - Registration of securities, business combinations:
04/03/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
03/09/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/09/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/06/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Quarterly results
03/06/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/06/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Exhibit 2.1    EXECUTION VERSION   AGREEMENT AND PLAN OF MERGER   BY AND AmONG   Adaptimmune therapeutics plc,   cm Merger sub, Inc.   AND   tcr 2 therapeutics inc.",
"Agreement”) is made and entered into as of March 5, 2023 , by and among Adaptimmune Therapeutics PLC , a public company limited by shares incorporated in England and Wales, TCR 2 Therapeutics Inc. , a Delaware corporation and [STOCKHOLDER] . Each of Parent, the Company and the Stockholder are sometimes referred to as a “Party” and collectively as the “Parties",
"VOTING AND SUPPORT AGREEMENT   This Voting and Support Agreement is made and entered into as of March 5, 2023 , by and among  Adaptimmune Therapeutics PLC , a public company limited by shares incorporated in England and Wales,  TCR 2 Therapeutics Inc. , a Delaware corporation and  [SHAREHOLDER] . Each of Parent, the Company and the Shareholder are sometimes referred to as a “Party” and collectively as the “Parties”. Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Merger Agreement .   RECITALS   A.              Concurrently with the execution and delivery of this Agreement, Parent, the Company and CM Merger Sub, Inc...",
"Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors Compelling clinical data with clear paths to products and multiple near-term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST",
"of Section 27 A of the Securities Act of 1933",
"significant operational advantages",
"Email to Employees"
02/14/2023 SC 13G/A PFM Health Sciences, LP reports a 3% stake in Adaptimmune Therapeutics PLC
01/31/2023 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
01/18/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/20/2022 8-K Quarterly results
12/02/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
10/25/2022 8-K Quarterly results
09/09/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy